Astrazeneca Plc Stock Performance
| AZN Stock | USD 208.40 0.00 0.00% |
On a scale of 0 to 100, AstraZeneca PLC holds a performance score of 10. The firm shows a Beta (market volatility) of 0.47, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, AstraZeneca PLC's returns are expected to increase less than the market. However, during the bear market, the loss of holding AstraZeneca PLC is expected to be smaller as well. Please check AstraZeneca PLC's value at risk, as well as the relationship between the skewness and day typical price , to make a quick decision on whether AstraZeneca PLC's price patterns will revert.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in AstraZeneca PLC are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. In spite of very unfluctuating basic indicators, AstraZeneca PLC displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 2.19 | Five Day Return 1.88 | Year To Date Return 14.11 | Ten Year Return 261.89 | All Time Return 4 K |
Forward Dividend Yield 0.0153 | Payout Ratio | Last Split Factor 1:2 | Forward Dividend Rate 3.2 | Dividend Date 2026-03-23 |
1 | ISPE Announces 2026 Facility of the Year Awards Submission Finalists at the 2026 ISPE Facilities of the Future Conference | 02/04/2026 |
2 | Eli Lilly Expands Its In Vivo Ambitions, Acquiring Cell Therapy Startup Orna for up to 2.4B | 02/09/2026 |
3 | Heres What Lifted AstraZeneca PLC in Q4 | 02/12/2026 |
4 | Pharma companies venture further afield in search of RD | 02/17/2026 |
5 | JJ to invest 1 billion in new Pennsylvania plant amid US manufacturing push | 02/18/2026 |
6 | Complement C5 Inhibitors C5 Receptor Antagonists Pipeline Market Research Report 2026 Soliris and Ultomiris from AstraZeneca and Piasky Have Set the Stage for N... | 02/19/2026 |
7 | FDA Approval For AbbVieAstraZenecas Combination Treatment Could Set New Standard For Slow Growing Blood Cancer | 02/20/2026 |
8 | Acromegaly Market Poised for Significant Expansion During the Forecast Period as New Treatment Options Emerge DelveInsight | 02/23/2026 |
| Begin Period Cash Flow | 5.4 B | |
| Total Cashflows From Investing Activities | -6.8 B |
AstraZeneca | Build AI portfolio with AstraZeneca Stock |
AstraZeneca PLC Relative Risk vs. Return Landscape
If you would invest 17,724 in AstraZeneca PLC on December 2, 2025 and sell it today you would earn a total of 3,121 from holding AstraZeneca PLC or generate 17.61% return on investment over 90 days. AstraZeneca PLC is generating 0.2905% of daily returns assuming volatility of 2.2276% on return distribution over 90 days investment horizon. In other words, 20% of stocks are less volatile than AstraZeneca, and above 95% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
AstraZeneca PLC Target Price Odds to finish over Current Price
The tendency of AstraZeneca Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 208.40 | 90 days | 208.40 | about 1.24 |
Based on a normal probability distribution, the odds of AstraZeneca PLC to move above the current price in 90 days from now is about 1.24 (This AstraZeneca PLC probability density function shows the probability of AstraZeneca Stock to fall within a particular range of prices over 90 days) .
AstraZeneca PLC Price Density |
| Price |
Predictive Modules for AstraZeneca PLC
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as AstraZeneca PLC. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.AstraZeneca PLC Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. AstraZeneca PLC is not an exception. The market had few large corrections towards the AstraZeneca PLC's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold AstraZeneca PLC, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of AstraZeneca PLC within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.19 | |
β | Beta against Dow Jones | 0.47 | |
σ | Overall volatility | 9.73 | |
Ir | Information ratio | 0.07 |
AstraZeneca PLC Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of AstraZeneca PLC for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for AstraZeneca PLC can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| AstraZeneca PLC has 29.7 B in debt with debt to equity (D/E) ratio of 0.89, which is OK given its current industry classification. AstraZeneca PLC has a current ratio of 0.79, suggesting that it has not enough short term capital to pay financial commitments when the payables are due. Nevertheless, prudent borrowing could serve as an effective mechanism for AstraZeneca to finance growth opportunities yielding strong returns. | |
| AstraZeneca PLC has a very strong financial position based on the latest SEC filings | |
| Latest headline from finance.yahoo.com: Acromegaly Market Poised for Significant Expansion During the Forecast Period as New Treatment Options Emerge DelveInsight |
AstraZeneca PLC Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of AstraZeneca Stock often depends not only on the future outlook of the current and potential AstraZeneca PLC's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. AstraZeneca PLC's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 3.1 B | |
| Cash And Short Term Investments | 5.7 B |
AstraZeneca PLC Fundamentals Growth
AstraZeneca Stock prices reflect investors' perceptions of the future prospects and financial health of AstraZeneca PLC, and AstraZeneca PLC fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on AstraZeneca Stock performance.
| Return On Equity | 0.23 | ||||
| Return On Asset | 0.0819 | ||||
| Profit Margin | 0.17 % | ||||
| Operating Margin | 0.22 % | ||||
| Current Valuation | 348.59 B | ||||
| Shares Outstanding | 1.55 B | ||||
| Price To Earning | 103.39 X | ||||
| Price To Book | 6.50 X | ||||
| Price To Sales | 5.50 X | ||||
| Revenue | 58.74 B | ||||
| Gross Profit | 47.99 B | ||||
| EBITDA | 19.83 B | ||||
| Net Income | 10.22 B | ||||
| Cash And Equivalents | 4.52 B | ||||
| Cash Per Share | 1.46 X | ||||
| Total Debt | 29.7 B | ||||
| Debt To Equity | 0.89 % | ||||
| Current Ratio | 0.81 X | ||||
| Book Value Per Share | 31.38 X | ||||
| Cash Flow From Operations | 14.57 B | ||||
| Earnings Per Share | 6.55 X | ||||
| Market Capitalization | 323.16 B | ||||
| Total Asset | 114.07 B | ||||
| Retained Earnings | 10.97 B | ||||
| Working Capital | (1.89 B) | ||||
| Current Asset | 16.01 B | ||||
| Current Liabilities | 14.87 B | ||||
About AstraZeneca PLC Performance
By examining AstraZeneca PLC's fundamental ratios, stakeholders can obtain critical insights into AstraZeneca PLC's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that AstraZeneca PLC is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 225.08 | 122.03 | |
| Return On Tangible Assets | 0.19 | 0.11 | |
| Return On Capital Employed | 0.16 | 0.24 | |
| Return On Assets | 0.09 | 0.10 | |
| Return On Equity | 0.21 | 0.33 |
Things to note about AstraZeneca PLC performance evaluation
Checking the ongoing alerts about AstraZeneca PLC for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for AstraZeneca PLC help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| AstraZeneca PLC has 29.7 B in debt with debt to equity (D/E) ratio of 0.89, which is OK given its current industry classification. AstraZeneca PLC has a current ratio of 0.79, suggesting that it has not enough short term capital to pay financial commitments when the payables are due. Nevertheless, prudent borrowing could serve as an effective mechanism for AstraZeneca to finance growth opportunities yielding strong returns. | |
| AstraZeneca PLC has a very strong financial position based on the latest SEC filings | |
| Latest headline from finance.yahoo.com: Acromegaly Market Poised for Significant Expansion During the Forecast Period as New Treatment Options Emerge DelveInsight |
- Analyzing AstraZeneca PLC's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether AstraZeneca PLC's stock is overvalued or undervalued compared to its peers.
- Examining AstraZeneca PLC's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating AstraZeneca PLC's management team can have a significant impact on its success or failure. Reviewing the track record and experience of AstraZeneca PLC's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of AstraZeneca PLC's stock. These opinions can provide insight into AstraZeneca PLC's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AstraZeneca PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. To learn how to invest in AstraZeneca Stock, please use our How to Invest in AstraZeneca PLC guide.You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Will Pharmaceuticals sector continue expanding? Could AstraZeneca diversify its offerings? Factors like these will boost the valuation of AstraZeneca PLC. If investors know AstraZeneca will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every AstraZeneca PLC data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 0.539 | Dividend Share 3.2 | Earnings Share 6.55 | Revenue Per Share | Quarterly Revenue Growth 0.041 |
The market value of AstraZeneca PLC is measured differently than its book value, which is the value of AstraZeneca that is recorded on the company's balance sheet. Investors also form their own opinion of AstraZeneca PLC's value that differs from its market value or its book value, called intrinsic value, which is AstraZeneca PLC's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because AstraZeneca PLC's market value can be influenced by many factors that don't directly affect AstraZeneca PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that AstraZeneca PLC's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether AstraZeneca PLC represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, AstraZeneca PLC's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.